Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healt...
2024-05-02 10:00:43 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...
2024-05-02 01:48:02 ET AtriCure, Inc. (ATRC) Q1 2024 Earnings Conference Call May 1, 2024 16:30 ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference C...
2024-05-01 16:27:26 ET More on AtriCure AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript AtriCure Q1 2024 Earnings Preview AtriCure upgraded at Oppenheimer on valuation Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for...
Worldwide revenue of $108.9 million – an increase of 16.4% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, t...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
2024-04-30 17:35:59 ET More on AtriCure AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript AtriCure upgraded at Oppenheimer on valuation AtriCure Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securi...
2024-04-23 08:34:50 ET More on AtriCure AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript AtriCure Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial information for AtriCure ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...